Skip to main navigation Skip to search Skip to main content

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

  • Bertrand Coiffier
  • , Evgenii A. Osmanov
  • , Xiaonan Hong
  • , Adriana Scheliga
  • , Jiri Mayer
  • , Fritz Offner
  • , Simon Rule
  • , Adriana Teixeira
  • , Jan Walewski
  • , Sven de Vos
  • , Michael Crump
  • , Ofer Shpilberg
  • , Dixie Lee Esseltine
  • , Eugene Zhu
  • , Christopher Enny
  • , Panteli Theocharous
  • , Helgi van de Velde
  • , Yusri A. Elsayed
  • , Pier Luigi Zinzani

Research output: Contribution to journal › Article › peer-review

95 Scopus citations

Fingerprint

Dive into the research topics of 'Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience